Vanda Pharmaceuticals Inc.
DE ˙ DB ˙ US9216591084
5,26 € ↑0,09 (1,74%)
2026-06-05
AKTIENPREIS
SecurityDE:VM4 / Vanda Pharmaceuticals Inc.
InstitutionAdvisory Services Network, LLC
Latest Disclosed Ownership21 shares
Latest Disclosed Value $ 145
Advisory Services Network, LLC ownership in VM4 / Vanda Pharmaceuticals Inc.

On May 15, 2026 - Advisory Services Network, LLC filed a 13F-HR form disclosing ownership of 21 shares of Vanda Pharmaceuticals Inc. (DE:VM4) valued at $121 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 17, 2026 disclosing 0 shares of Vanda Pharmaceuticals Inc.. The current value of the position is $110 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F VANDA PHARMACEUTICALS INC COM Stock 921659108 21 21 0 0.0000
2026-02-17 2025-12-31 13F VANDA PHARMACEUTICALS Stock 921659108 0 -21 -100.00 0 0.0000
2025-11-18 2025-09-30 13F VANDA PHARMACEUTICALS Stock 921659108 21 21 0 0.0000
2021-02-09 2020-12-31 13F VANDA PHARMACEUTICALS Stock 921659108 0 -150 -100.00 0 -100.00
2020-11-16 2020-09-30 13F VANDA PHARMACEUTICALS Stock 921659108 150 150 1 0.0000
2017-08-17 2017-06-30 13F VANDA PHARMACEUTICALS INC COM Stock 921659108 0 -500 -100.00 0 -100.00
2017-04-28 2017-03-31 13F VANDA PHARMACEUTICALS INC COM Stock 921659108 500 -400 -44.44 7 -53.33 0.0010
2016-10-07 2016-09-30 13F VANDA PHARMACEUTICALS Stock 921659108 900 -500 -35.71 15 -6.25 0.0028
2016-07-27 2016-06-30 13F VANDA PHARMACEUTICALS Stock 921659108 1,400 -2,650 -65.43 16 -52.94 0.0036
2016-04-21 2016-03-31 13F VANDA PHARMACEUTICALS Stock 921659108 4,050 -1,300 -24.30 34 -32.00 0.0093
2016-01-27 2015-12-31 13F VANDA PHARMACEUTICALS INC COM Stock 921659108 5,350 0 0.00 50 -16.67 0.0161
2015-10-01 2015-09-30 13F VANDA PHARMACEUTICALS INC COM Stock 921659108 5,350 500 10.31 60 -1.64 0.0181
2015-07-02 2015-06-30 13F VANDA PHARMACEUTICALS INC COM Stock 921659108 4,850 4,850 61 0.0180
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.